Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm&#39;s canal cells

ABSTRACT

The present invention provides methods of inhibiting cadherins between Schlemm&#39;s canal cells, to a patient suffering from glaucoma as well as screening for substances that inhibit cadherins between the Schlemm&#39;s canal cells.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of provisional application serial No. 60/447,490 filed Feb. 14, 2003, the contents of which are incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] Funding for the work described herein was provided in part by the Federal government, which has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0003] 1. Field of the Invention

[0004] The present invention relates to the modulation of aqueous humor outflow by targeting cadherins between Schlemm's canal cells and methods of treating glaucoma by employing cadherin inhibitors.

[0005] 2. Description of the Background

[0006] Glaucoma is the second leading cause of blindness in the United States.( Quigley H. Br J Ophthalmol. 1996;80:389-393.) The most common form, open-angle glaucoma, is characterized by elevated intraocular pressure (IOP) that compresses nerve axons resulting in loss of ganglion cells and subsequent loss of vision.(Quigley H et al Am J Ophthalmol. 1983;95:673-691) IOP is maintained by a balance between production and removal of aqueous humor from the eye. A reduction in removal aqueous humor elevates IOP and often leads to glaucoma. (Rohen J. Ophthalmol.1983;95:673-691) The primary pathway in humans for removal of aqueous humor consists of the trabecular meshwork (TM) and the canal of Schlemm (SC). The majority of resistance to outflow of aqueous humor is generated deep in the TM (juxtacanalicular region) near or at the inner wall of SC.(Grant W M. Arch Ophthalmol. 1963;69:783; Bill A, Maepea O. Mechanisms and routes of aqueous humor drainage. Philadelphia: W B Saunders, 1975:206-226).

[0007] Intercellular adhesion is mediated by specific cell surface adhesion molecules. Two classes of transmembrane cell-cell adhesion molecules are present in adherens junctions of endothelium. Associated with VE-cadherin in discrete but separate domains in the adherens junction is PECAM-1 (CD31), which is a member of the immunoglobulin superfamily of adhesion molecules. (Ferrero E, et al FEBS Letters. 1995;374:323-326). While calcium-independent intercellular adhesion has been shown to be through PECAM-1, VE-cadherin interactions are calcium-dependent. Cadherins mediate cell-cell adhesion through specific protein-protein interactions of cytoplasmic domains (Nose A, et al Cell. 1990;61:147-155). The conserved cytoplasmic domain of cadherins is required for function and deletion of the cytoplasmic domain has been shown to inhibit cell-cell adhesion.(Kintner C Cell. 1992;69:225-236). A family of intracellular proteins termed the catenins (α-catenin, β-catenin, γ-catenin, p120ctn) is associated with the cytoplasmic domain of cadherins and links the complex to cortical actin filaments (Adams C Curr Opinion Cell Biol. 1998;10: 572-577). While α-catenin is the direct linkage with actin filaments, β-catenin regulates the association of the cadherin complex with the cytoskeleton and p120ctn regulates high affinity binding of the complex between adjacent cells (Roura S et al J Cell Biol. 1999;274:36734-36740; Thoreson M et al Cell Biol. 2000;148:189-202). The catenins function in the dynamic regulation of cadherin adhesive function. Tyrosine and serine/threonine phosphorylation of the cadherin/catenin complex modulate the adhesive function of the adherens junction complex by decreasing the affinity of cadherin for an adjacent cadherin or the affinity of the cadherin/catenin complex with the F-actin cytoskeleton (Roura S et al J Cell Biol. 1999;274:36734-36740; Rajasekaran A, et al J Cell Biol. 1996; 132:451-463). Studies suggest that the catenins also function in the assembly of ZO-1 into tight junctions by mobilization of the ZO-1 from the cytosol to the cell surface (Rajasekaran A, et al J Cell Biol. 1996;132:451-463). Therefore, regulation of the balance of multiple cell-cell adhesion molecules in response to soluble and mechanical factors is likely to play a role in control of complexity and interdependence of cell junctions between SC cells (Noria S et al Circ Res. 1999;85:504-514).

[0008] In general, monoclonal antibodies against the first amino terminal repeat of VE-cadherin (that include EC 1) increase permeability of endothelial monolayers in vitro and in vivo (Corada M, et al Blood 2001 ;97:1679-1684). Upon treatment with anti-VE-cadherin antibodies, VE-cadherin redistributes on cell surface away from intercellular junctions but does not change the localization of CD31 or tight junction proteins. Thus, VE-cadherin is a key protein involved in regulating permeability of vascular endothelial (Haselton F, Heimark R. L. J Cell Physiol. 1997;171:243-251; Wong R, et al Am. J. Physiol. 1999;276:H736-H748).

[0009] Currently, the primary goal in the treatment of people with glaucoma is to reduce intraocular pressure either by decreasing inflow or increasing outflow of aqueous humor. There are several currently used approaches to treat glaucoma. Current pharmacological treatments in most cases insufficiently reduce pressure in those with glaucoma. Second, no commonly used method targets the primary outflow structures of the eye; a location of pathology in most glaucomas. Third, laser trabeculoplasty, the most common surgical intervention, involves damaging trabecular meshwork tissue that results in increased remodeling and increased outflow that only lasts for a short time (usually months). Fourth, if all the above do not lower intraocular pressure, a major surgical procedure, trabeculectomy, is performed. This surgical procedure has many complications associated and is only marginally successful in most cases, lasting 1-5 years.

[0010] There remains an urgent need for new and effective therapies to treat glaucoma.

SUMMARY OF THE INVENTION

[0011] The present invention is based on the discovery of the unique expression of VE-cadherin proteins between Schlemm's canal cells in the human outflow pathway thereby providing a target to decrease intraocular pressure that in turn provides a treatment for glaucoma patients.

[0012] Accordingly, one aspect of the present invention is to a method of treating glaucoma by administering to a patient in need thereof, one or more cadherin inhibitors, or compounds that decrease cadherin homotypic binding or cadherin expression to the patient in an amount to decrease cadherin-mediated adhesion or adhesion affinity between Schlemm's canal cells thereby increasing outflow facility and decreasing intraocular pressure and treating glaucoma.

[0013] In another aspect of the present invention, methods of screening for substances that inhibit the activity of cadherins between Schlemm's canal cells is also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:

[0015]FIG. 1. Characterization of VE-cadherin by immunolocalization and immunoblotting in vascular endothelium of the retina. This is a distinct compartment in the eye from the Schlemm's cell canal. (A) Whole mount immunolocalization of VE-cadherin in a large retinal arteriole. (B) Immunolocalization of VE-cadherin in retinal capillaries. (C) Immunolocalization of VE-cadherin in retinal endothelial cells cultured on glass coverslips. (D) Immunoblotting for VE-cadherin with equivalent protein from cell lysates: lane 1, bovine aortic endothelial cells (BAEC); lane 2, bovine aortic smooth muscle cells (BASMC); lane 3, rat aortic smooth muscle cells (RASMC); lane 4, human aortic smooth muscle cells (HASMC); lane 5, human iliac vascular endothelial cells (HIVEC); lane 6, Bovine retinal endothelial cells (BREC). Data shown are representative experiments of 3 total for each condition.

[0016]FIG. 2. Immunoblot analyses of VE-cadherin and PECAM-1 in cells of human outflow pathway. Immunoblots were probed with antibodies against VE-cadherin, PECAM-1 or β-catenin. The first lane is a positive control and contains lysate prepared from BAECs. Lane 2 contains lysate prepared from outflow tissue containing SC (SC/TM) that was microdisected from human cadaveric eyes. Lane 3 contains lysate prepared from cultured human trabecular meshwork cells. Data shows one representative experiment of four total.

[0017]FIG. 3. Expression of endothelial-specific proteins by human Schlemm's Canal cells. Sequential cryosections of anterior chambers from human cadaveric eye tissue were analyzed for expression of VE-cadherin (panels A and B) and PECAM-1 (panels C and D) by immunofluorescence microscopy. Arrows indicate specific labeling. Inset of panel B shows localization of VE-cadherin labeling to cell borders. Background immunofluorescence was recorded in the absence of primary antibodies (Control, panels E and F). Tissue sections were observed at two magnifications (low: panels A, C and E and high: panels B, D and F). Internal positive controls were endothelial cells that lined collector channels (inset panel F) in same tissue sections as experimental group. Data shown is one representative experiment of seven total using seven different eye bank eyes.

[0018]FIG. 4. By RT-PCR, cultured human SC cells express VE-cadherin mRNA. Total RNA from dissected human trabecular meshwork/SC tissue (SC/TM, lane 1, panel A) and cultured human SC cells (SC, lane 1, panel B) was analyzed for presence of VE-cadherin mRNAs by RT-PCR. To control for contamination of samples by genomic DNA, RNA was treated with RNase A before RT (lanes 2) or no template was used in PCR reaction (lanes 3). As a positive control, total RNA from HUVEC was used as template in RT-PCR (lane 1). Two VE-cadherin-specific primer sets were used. In panel A the expected product size was 308 and in panel B the expected size was 373 base pairs. All PCR products were sequenced and found to correspond identically to human VE-cadherin. Lanes M contain 100 bp marker ladders. Data shown is one representative experiment of three total for each preparation.

[0019]FIG. 5: Effect of hydrostatic pressure and Na₂EDTA on transendothelial electrical resistance across cell monolayers. After 15 minutes of stable TEER at no pressure, either human Schlemm's canal cells (panel A) or MDCK cells (panel B) were exposed to hydrostatic pressure (P=4-6 mmHg for SC and 14-16 mm Hg for MDCK). At the 20-minute mark, chambers containing cell monolayers were exchange with normal medium (chamber exchange). At the 30-minute mark, chambers containing cell monolayers were exchanged with medium containing Na₂EDTA (panel A, 5 mM and panel B, 25 mM). At the 35-minute mark, chambers containing cell monolayers were exchanged with normal medium (rinse). Shown is one experiment for each cell type of 4-5 total experiments.

[0020]FIG. 6: Effect of hydrostatic pressure on change in transendothelial electrical resistance (TEER) across cell monolayers. Shown as histograms are the mean changes (±SEM) in TEER across Schlemm's Canal (SC) and MDCK cell monolayers during exposure to hydrostatic pressure either in the absence (panel A; 15 min. baseline) or presence (panel B) of Na₂EDTA (5 mM for SC and 25 mM for MDCK for 5 min; measurement period=5 min. following exposure). Data represent combined data from 4-5 experiments for each cell type.

[0021]FIG. 7: Effect of Na₂EDTA on hydraulic conductivity (HC) of cell monolayers. HC was calculated from continuous recording of pressure and flow across cell monolayers. After 30 minutes of stable HC across cell monolayers both before and after a chamber exchange with normal medium, SC (panel A) or MDCK (panel B) cells were subjected to medium containing Na₂EDTA (5 mM for SC and 25 mM for MDCK). After 5 minutes of exposure, cells were rinsed with normal medium and HC was evaluated for 15 minutes. Monitoring of HC continued uninterrupted. Each line represents one independent experiment.

[0022]FIG. 8: Effect of Na₂EDTA on cell-cell associations of Schlemm's canal monolayers. Shown in panel A is a phase-contrast image of cultured SC cell monolayers obtained by video capture before treatment with Na₂EDTA. Cells were exposed to 10 mM Na₂EDTA for 5 minutes and rinsed with normal medium and were visualized continuously. Shown in panels B and C is the same field as in panel A, sixty and ninety seconds after treatment, respectively. The tips of arrows indicate cell margins. Retraction fibers are seen between the arrow tips in panels B and C. Shown is one representative experiment of 10 total. Images in all panels were videocaptured at the same magnification.

DETAILED DESCRIPTION OF THE INVENTION

[0023] The present invention is based on evidence that resistance to outflow is, in part, mediated by the intercellular junctions between cells at or near the inner wall of SC. Thus, intercellular junctions can influence outflow function in at least three different ways. First, cell-cell junctional complexes maintain a contiguous inner wall of SC and limit paracellular fluid flow.(Underwood J et al Am J Physiol. 1999;277:C330-C342) Second, because of a discontinuous basal lamina, SC cells may rely on cell-cell attachments from juxtacanalicular TM cells for support and/or communication.(Johnstone M. Invest Ophthalmol Vis Sci. 1979;18:44-51) Third, cell-cell junctions join cytoskeletal elements from cell neighbors, enable the transduction of mechanical force between cells and allow the outflow tissues to function as a unit. (Wiederholt et al Prog Retinal Eye Res. 2000;19:271-295).

[0024] Accordingly, the present invention provides a method of treating glaucoma by administering one or more cadherin inhibitors, or compounds that decrease cadherin homotypic binding, affinity, or cadherin expression to a mammalian patient in need thereof, in an amount such that the cadherins between the Schlemm's canal cells are inhibited in such a way to decrease intraocular pressure and/or increase intraocular outflow and in turn treat glaucoma in the mammalian patient. This invention also relates to methods for specifically targeting therapeutics toward Schlemm's canal cells by taking advantage of their unique expression of VE-cadherin amongst the lining cells of the outflow pathway. In one embodiment, the homotypic binding of cadherins is inhibited. In another embodiment, the present invention also relates to methods for down-regulating protein and mRNA expression of cadherins.

[0025] Using electron and immunofluorescence microscopy, three different morphological types of cell-cell junctions have been described in the outflow pathway: tight junctions, gap junctions and adherens junctions.(Raviola G InvestOphthalmol Vis Sci. 1981 ;21 :52-72; Grierson I Exp Eye Res. 1975;20:505-522; Bhatt et al Invest Ophthalmol Vis Sci. 1995;36:1379-1389; Grierson I. Graefes Arch Klin Exp Ophthalmol. 1974;192:89-104). The lateral membrane between SC cells consists of a complex of these three junctional elements, which function together as a unit to stabilize cell-cell interaction. In contrast, the intercellular junction between SC and TM cells contains only gap and adherens junctions.

[0026] Further support for the present invention is that the proteins that form adherens junctions likely contribute to regulation of outflow resistance is as follows. First, previous studies have shown that depletion of extracellular calcium dramatically decreases outflow resistance by dissociating cell-cell interactions, thereby implicating cadherin proteins as candidates responsible for the adhesive forces in intercellular junctions of outflow cells (Bill A et al Invest Ophthalmol Vis Sci. 1980;19:492-504). Second, the adhesion of these proteins is highly dynamic and regulated by calcium dependent interactions of the extracellular domains and the interactions of the cytoplasmic domains with the actin cytoskeleton (Adams Curr Opinion Cell Biol. 1998;10:572-577;Kintner C. Cell. 1992;69:225-236). Third, increased expression of the cell adhesion protein, endothelial-leukocyte adhesion molecule (ELAM-1), was found exclusively in glaucomatous eyes compared to age-matched controls (Wang N et al Nature Med. 2001 ;7:304-309). Lastly, extensive work in vascular endothelium has demonstrated the active participation of VE-cadherin in maintaining barrier function; (Yuan S. Microcirculation. 2000;7:395-403;Corada M et al Proc Natl Acad Sci USA. 1999;96:9815-9820) therefore providing a biological precedent.

[0027] Specifically targeting Schlemm's canal can be accomplished in at least two ways. First, expression of proteins that interfere with junction formation or can be targeted to Schlemm's canal cells in the conventional outflow pathway using an expression vector that contains the cadherin-5 gene promoter region (CDH5 on chromosome 16). The region contains the cis-regulatory elements necessary for VE-cadherin mRNA expression. Second, monoclonal antibodies or interfering peptides (or peptide mimetics) can be injected into the anterior chamber of eyes (or applied topically) and directed naturally to primary outflow tissues (due to aqueous humor flow pattern), in addition other inhibitory substances as described herein may also be used. Interference with cadherin adherins junction, e.g., VE-cadherinjunction, formation will result in increased permeability of Schlemm's canal, increased outflow facility and decreased intraocular pressure.

[0028] The advantages to the present invention over currently used approaches are many. As discussed above current pharmacological treatments in most cases insufficiently reduce pressure in those with glaucoma nor do the treatments target the primary outflow structures of the eye; the location of pathology. The most common surgical intervention, laser trabeculoplasty involves damaging trabecular meshwork tissue that results in increased remodeling and increased outflow that only lasts for a short time (usually months). If all the above do not lower intraocular pressure, a major surgical procedure, trabeculectomy, is performed. This surgical procedure has many complications associated and is only marginally successful in most cases lasting 1-5 years.

[0029] The region at or near Schlemm's canal is thought responsible for generating greater than 70% of resistance to aqueous humor outflow (Grant WM. Arch Ophthalmol 1963;69:783; Bill A, Maepea O. Mechanisms and routes of aqueous humor drainage. Philadelphia: W B Saunders, 1975:206-226). The use of interventions that target cadherins, e.g., VE-cadherin, will directly affect the primary outflow pathway, will theoretically not damage trabecular meshwork tissue (no VE-cadherin protein is expressed here), is reversible and will theoretically act to flush accumulated debris in outflow pathway.

[0030] Cadherin proteins are known, for example, the sequence of N-cadherin is accessible from Genbank under the accession number X54315 and the sequence of the VE-cadherin protein is accessible from Genbank under the accession number X59796. The nucleotide sequence of N-cadherin is shown in SEQ ID NO:5 and the corresponding amino acid sequence is shown in SEQ ID NO:6. The nucleotide sequence of VE-cadherin is shown in SEQ ID NO:7 and the corresponding amino acid sequence is shown in SEQ ID NO:8. Other cadherinsequences are accessible from GenBank under the numbers NM001795, X79981, AB035304, U84722, AC012325, AC132186, NM001792, BC036470, S42303, M34064, X57548, AC015933, Z27432, AC006249, Z27420, AK129728, Z27419, AY008776, and Z27435.

[0031] Accordingly, the cadherins that are inhibited herein are preferably those described above, i.e., SEQ ID NOS:6 and/or 8 as well as the proteins that are at least 70%, preferably at least 80%, more preferably at least 90% identical to those sequences. In another embodiment, the cadherin that is to be inhibited are encoded by polynucleotide sequence with at least 70%, preferably 80%, more preferably at least 90%, 95%, and 97% identity to the cadherin sequences described above, e.g., SEQ ID NOS:5 and/or 7, these polynucleotides will hybridize under stringent conditions to the coding or non-coding polynucleotide sequence above.

[0032] The terms “stringent conditions” or “stringent hybridization condition” includes reference to conditions under which a polynucleotide will hybridize to its target sequence, to a detectably greater degree than other sequences (e.g., at least 2-fold over background). Stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides), for example, high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 0.1×SSC at 60 to 65° C. (see Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes, Part I, Chapter 2 “Overview of principles of hybridization and the strategy of nucleic acid probe assays”, Elsevier, New York (1993); and Current Protocols in Molecular Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995)). Amino acid and polynucleotide identity, homology and/or similarity can be determined using the ClustalW algorithm, MEGALIGN™, Lasergene, Wis.)

[0033] In one embodiment of the present invention inhibiting cadherin also comprises treating, ameliorating, and/or providing a prophylactic therapeutic effect for those individuals suffering from glaucoma. By “treating” is meant the slowing, interrupting, arresting or stopping of the progression of the disease or condition and does not necessarily require the complete elimination of all disease symptoms and signs. “Preventing” is intended to include the prophylaxis of the neurological disease, wherein “prophylaxis” is understood to be any degree of inhibition of the time of onset or severity of signs or symptoms of the disease or condition, including, but not limited to, the complete prevention of the disease or condition. The substances which inhibit cadherin(s) are herein collectively termed “cadherin inhibitor(s).”

[0034] Polyclonal, monoclonal and/or fragments (e.g., Fab fragments) of antibodies that specifically bind to the cadherin proteins described herein may be used so long as they inhibit the function of the cadherins according to the disclosure herein. Obtaining polyclonal, monoclonal and/or functional fragments thereof is conventional and is described, for example, in Harlow and Lane “Using Antibodies: A Laboratory Manual” (D Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1999).

[0035] Cadherin adhesive functions depend on both the homotypic interactions of the extracellular domains on adjacent cells as well as the interaction of the cytoplasmic domain with the actin cytoskeleton. Specific peptides to the HAV sequence in the first cadherin repeat in E-cadherin and N-cadherin have been shown to interfere with adhesive functions (Blaschuk et al, Dev Biol 1990 139, 227-229; Williams et al, Neuron 1994 13,583-594; Noe et al J Cell Science 1999; 112, 127-135). This sequence is not present in human VE-cadherin. Alignment of the amino acids in the extracellular domain of VE-cadherin with that of N-cadherin and E-cadherin indicates that peptides containing the sequence VIV may have similar activities. Activation of signaling pathways that increase endothelial permeability have been found to alter the cytoplasmic interactions of VE-cadherin. For example, the formation of cadherin based adherens junctions (AJs) affects cytoskeletal actin arrangement that Rho GTPases (Rho, Rac and Cdc42) regulate the state of actin polymerization. Therefore, peptides comprising the amino acid sequence of HAV and/or the amino acid sequence of VIV may also be used as cadherin inhibitors.

[0036] Additional inhibitors of cadherin proteins are described, for example, in U.S. Pat. Nos. 6,277,824, 6,326,352, 6,346,512, 6,472,367, 6,472,368, 6,551,994, 6,569,996, 6,610,821, and 6,638,911, the relevant disclosures of which are incorporated herein by reference.

[0037] The discovery of the role cadherins between Schlemm's canal cells and, in particular, in modulating intraocular pressure, for example, in glaucoma patients, is significant in that it permits the identification of additional cadherin inhibitors useful for the treatment of glaucoma. Accordingly, another object of the present invention is to provide methods of screening for a substance that inhibits the function of cadherins, e.g., VE-cadherin, between Schlemm's canal cells and further for a substance that decreases intraocular pressure in a patient in need thereof. Testing the compounds for these attributes can be performed as described in Examples 1 and 2, which follows. In this method, cultured SC cells or cells obtained from a tissue sample are contact with the substance to be screened and the detection of the ability of that substance to inhibit cadherin activity between the SC cells or the ability of that substance to increase hydraulic conductivity and/or transendothelial electrical resistance between the SC cells is indicative that the substance is capable of inhibiting the cadherins, and in turn, treating glaucoma. The substances can be tested in accepted human models of the human outflow pathway: a) human anterior chamber perfusion model and b) live animal model (monkey). Test data with a similar strategy in the vascular system are published in mice and cell culture systems (PNAS, 96:9815-9820, 1999; Blood, 97:1679-1684, 2001). Further, the substance can be tested by measuring its effect on adhesion of cultured SC cells to microtiter plates that have been precoated with fusion proteins comprising all or a portion of the extracellular domain of VE-cadherin.

[0038] The substances may be biological macromolecules, e.g., proteins, or other organic chemical molecules.

[0039] The cadherin inhibitors may be administered in a variety of dosage forms that include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, caged compounds, and injectable or infusible solutions. The preferred form depends upon the mode of administration.

[0040] The composition may be in the form of a liquid, slurry, or sterile solid that can be dissolved in a sterile injectable medium before use. The parenteral administration is preferably intravenously. This injection can be via a syringe or comparable means. This may contain a pharmaceutically acceptable carrier. Alternatively, the compositions, e.g. containing cadherin inhibitors, may be administered via a mucosal route, in a suitable dose, and in a liquid form.

[0041] The mammal in need thereof is understood to mean one that suffers from glaucoma and/or related ocular disease that may benefit from a decrease in intraocular pressure. Any mammal in need thereof can be treated, for example, a guinea pig, dog, cat, rat, mouse, horse, cow, sheep, monkey or chimpanzee. In a preferred embodiment, the mammal is a human.

[0042] A therapeutically effective amount of the cadherin inhibitors as described herein can be used either singularly or in combination and should be used in an amount that results in some cadherin inhibition and glaucoma therapeutic effect. Such an amount can range from about 100 ng to about 10 mg/kg body weight per inhibitor or as a combination and can be determined based on age, race, sex, and other factors based on the individual patient. When the inhibitors are administered in combination, they may be premixed prior to administration, administered simultaneously, or administered singly in series.

[0043] In another embodiment, the present invention also provides a device especially suited for slow release and constant long-term application that may be an implanted mini-pump, preferably implanted subcutaneously (for example, as described in Edith Mathiowitz; (Ed.), Encyclopedia of Controlled Drug Delivery, John Wiley & Sons vol. 2, pp. 896-920, 1999). Such pumps are known to be useful in insulin therapy. Examples of such pumps include those manufactured/distributed by Animas, Dana Diabecare, Deltec Cozm, Disetronic Switzerland, Medtronic, and Nipro Amigo as well as those described, for example, in U.S. Pat. Nos.5,474,552; 6,55,8345; 6,122,536; 5,492,534; and 6,551,276, the relevant contents of which are incorporated herein by reference.

[0044] The route of administration can include the typical routes including, for example, orally, subcutaneously, transdermally, intradermally, rectally, vaginally, intramuscularly, intravenously, intraarterially, by direct injection to the brain, and parenterally. In addition, in some circumstances, pulmonary administration may be useful, e.g., pulmonary sprays and other respirable forms. In preferred embodiments, the route for administration is topical eye drops or intraocular injection.

[0045] The above-described inhibitors can be formulated for medical purposes according to standard procedures available in the art, e.g., a pharmaceutically acceptable carrier (or excipient) can be added. A carrier or excipient can be a solid, semi-solid or liquid material which can serve

[0046] as a vehicle or medium for the active ingredient. The proper form and mode of administration can be selected depending on the particular characteristics of the product selected, the disease, or condition to be treated, the stage of the disease or condition, and other relevant circumstances (Remington's Pharmaceutical Sciences, Mack Publishing Co. (1990)). The proportion and nature of the pharmaceutically acceptable carrier or excipient are determined by the solubility and chemical properties of the substance selected the chosen

[0047] route of administration, and standard pharmaceutical practice. The pharmaceutical preparation may be adapted for oral, parenteral or topical use and may be administered to the patient in the form of tablets, capsules, suppositories, solution, suspensions, or the like. The growth factors, derivatives thereof, a nucleic acid coding sequence thereof of the present

[0048] invention, while effective themselves, can be formulated and administered as pharmaceutically acceptable salts, such as acid addition salts or base addition salts, for purposes of stability, convenience of crystallization, increased solubility, and the like.

[0049] Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

EXAMPLES Example 1

[0050] Because the inner wall of SC constitutes the only continuous monolayer of cells in the outflow pathway, describes the cadherin subtype(s) expressed by these cells and there utility for increasing outflow to treat glaucoma.

[0051] Materials and Methods

[0052] Antibodies

[0053] For identification of VE-cadherin in intercellular junctions two monoclonal antibody preparations were used. An anti-VE-cadherin (clone 55-7H1) was purchased from Pharmingen (San Diego, Calif.) and a second murine monoclonal antibody (clone 9H7) was isolated using the following approach. Balb/C mice were immunized at two subcutaneous sites with 10⁶ human umbilical vein endothelial cells (HUVECs) in phosphate-buffered saline (PBS). Beginning four weeks after the initial immunization, mice were immunized three times at two-week intervals. The spleens were removed and fused with NS-1 myeloma cells (American Type Culture Collection, Manassas, Va.) with PEG1500 (Eastman Kodak). Production, growth, and dilution subcloning of the hybridomas were done by standard methods (Heimark R et al J Cell Biol. 1990; 110:1745-1756). Hybridoma supernatants were screened by ELISA assays on rat brain endothelial cells, bovine aortic endothelial cells (BAECs), and HUVECs cultured in 96 well plates using a Molecular Devices microplate reader (Heimark R et al J Cell Biol. 1990; 110:1745-1756). Wells positive on the three endothelia were screened by immunoblotting with total endothelial cell lysates on the three types of endothelium with the expected molecular weight for VE-cadherin (130 kD). Clones were further tested by immunoblotting with a bacterial fusion protein containing the first two extracellular domains of V-cadherin. Supernatants of selected clones were tested for their ability to block calcium-dependent cell-cell adhesion of HUVECs. These antibody preparations were used at a 1:1000 dilution in both immunofluorescence microscopy and western blot studies. Antibodies specific for PECAM-1 (R&D Systems, Minneapolis, Minn.) were used at a 1:500 dilution in immunofluorescence studies and 1:2000 dilution in western blot studies. Antibodies specific for β-catenin were purchased from Sigma Chemical Co. (St. Louis, Mo.) and used at a 1:5000 dilution in western blot studies.

[0054] Cell Culture

[0055] Human cadaveric eye tissue was obtained from the Donor Network of Arizona, the San Diego Lions Eye Bank and Lions Eye Bank of Central Florida within 48 hours of death for whole eyes stored in moist chambers, and 96 hours for non-transplantable corneal anterior segments stored in Optisol (Chiron Vision, Clairmont, Calif.). Human SC cells were isolated from cadaveric eye tissue using gelatin-coated cannulas as described previously. (Stamer W et al Invest Ophthalmol Vis Sci. 1998;39:1804-1812).

[0056] Briefly, the anterior chamber of human cadaveric eyes was cut into 8 equal and radially symmetric “wedge” shaped pieces. Using a Topcon (Paramus, N.J.) operating microscope, a gelatin-coated suture (6-0 sterile nylon monofilament, Wilson Ophthalmic, Mustang, Okla.) was gently inserted into the lumen of SC and advanced into the canal. The cannulated pieces of tissue were placed in culture (Dulbecco's Modified Eagle Medium, DMEM, containing 10% fetal bovine serum, 100 units/ml penicillin G sodium, and 100 m g/ml streptomycin sulfate (Life Technologies, Grand Island, N.Y.)) and maintained at 37° C. in humidified air containing 7% CO2 for at least 3 weeks. Sutures were removed from SC and cells seeded onto 3-cm culture plates. The cell strains used in this study were isolated from non-glaucomatous donor eye tissues from four different individuals (SC3, SC6 and SC7 and SC20) of ages 55, 45, 50 and 50 years, respectively, and all have been characterized previously.

[0057] Bovine retinal endothelial cells (BREC) were isolated from bovine retinas according to the procedure of Gitlin & D'Amore (Microvasc Res. 1983 Jul;26(1):74-80) and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS; Intergen, Purchase, N.Y.) penicillin/streptomycin plus retinal extract in a 37° C., 5% CO2 atmosphere on fibronection coated plates (Gitlin J, Microvasc Res. 1983;26:7480).After two passages they were cultured on gelatin coated dishes without retinal extract. The cells bind Dil-AcLDL and are immunolabeled by anti-von Willebrand factor. Endothelial cells were isolated from adult bovine aortas (BAEC) and grown in culture as previously described 25 in DMEM containing 10% FBS. Human umbilical vein and iliac vein endothelial cells (HIVEC) were isolated from normal veins (Gimbrone M, et al J Cell Biol. 1974;60:673-684). These cultures were propagated in Medium 199 with 15% FBS supplemented with endothelial cell growth factor (25 m g/ml, Collaborative Research, Waltham, Mass.) and heparin (90 m g/ml, Sigma). Smooth muscle cells were isolated from human rat and bovine aortas by collagenase dispersion (Geisterfer A et al Circ Res. 1988;62:749-756).

[0058] Cadherin Expression Screening Studies

[0059] A PCR with cDNA generated by reverse transcription of total RNA from SC cells was performed, using degenerate primers to amplify multiple cadherin subtypes (Suzuki S et al Cell Regulation. 1991 ;2:261-270).cDNA was amplified from 1 μg of DNase 1 treated total and the cDNA product was used in a 25 μl PCR reaction using the 5′ oligonucleotide primer AATGAATTCGTNTTYGAYTAYGARGG (SEQ ID NO:1) and the 3′ primer AATGAATTCRTCNGCNAGYTTYTTRAA (SEQ ID NO:2). The reaction products were next separated by a 4% agarose gel electrophoresis (3% Nusieve GTG agarose, and 1% Seakem ME agarose, FMC BioProducts, Rockland, Me.), and a cDNA fragment of about 150 bp was extracted, digested with EcoR1, and ligated into pBluescript. Bacteria (DH5,Life Technologies, Grand Island, N.Y.) were transformed and individual colonies were selected by color and antibiotic resistance. Plasmid DNA was isolated and subsequently sequenced.

[0060] Whole Mount Immunolabeling

[0061] Using a whole mount immunolabeling technique the inter-cellular junctions in venous and arterial segments of the retinal vasculature were labeled with anti-VE-cadherin (monoclonal antibody 9H7). Bovine retinas were dissected, fixed in 4% para-formaldehyde for 30 minutes, then permeabilized with CSK buffer containing 0.5% triton X-100, 10 mM PIPES (pH 6.8), 50 mM NaCl, 3mM MgCl2 and 0.3 M sucrose for an hour at 4° C. The retinas were blocked and incubated with the primary antibody in blocking solution. After washing the retinas with at least 5 changes of CMF/PBS with 0.1% BSA, the biotinylated-secondary anti-body was added for two hours, and then washed overnight. FITC-conjugated strepavadin was added and incubated for 30 min and then washed extensively before mounting.

[0062] Indirect Immunofluorescence Microscopy of Frozen Sections

[0063] Indirect immunofluorescence microscopy was performed on fresh frozen human eye tissue containing outflow structures. Tissue wedges that include angle structures were dissected from human eye bank eyes and embedded in OCT compound, frozen in a dry ice/ethanol bath and sectioned (8 m m). Sections on slides were fixed in 50% methanol/50% acetone and air-dried. Fixed sections of tissue were rehydrated in PBS, blocked with 10% goat serum in PBS containing 0.1% triton X-100 and incubated overnight with monoclonal IgG (1:1000 dilution, clone 9H7) or PECAM-1. Goat serum (10%, Sigma Chemical) and triton X-100 (0.1%, Sigma Chemical) were included in incubations to inhibit non-specific binding of antibodies to tissues. Following antibody incubations, tissue sections were washed extensively (4×4 ml×15 min) in phosphate-buffered saline containing 0.1% triton X-100.

[0064] Specific binding of antibodies to receptor was detected using CY3-conjugated goat anti-mouse immunoglobulin-G (IgG) or CY3-conjugated goat anti-rabbit IgG at a 1:1000 dilution (Jackson Immunoresearch Laboratories, West Grove, Pa.). Tissue sections were incubated with secondary antibodies for 2 hours and washed extensively before viewing. Background fluorescence was indicated in tissues processed in the absence of primary antibodies. Labeled tissue sections were visualized and photographed digitally using an Olympus IX70 inverted fluorescence microscope with a Magnifire digital camera (Olympus, Melville, N.Y.).

[0065] Total RNA Isolation

[0066] Total RNA was isolated from tissue dissected from human outflow pathway (including SC) and confluent cultures of SC cells in 10 cm culture plates using Trizol reagent according to the manufacturers recommendations (Life Technologies). Following extraction, RNA was precipitated using ice-cold ethanol, resuspended in diethyl pyrocarbonate (Sigma Chemical Co.)-treated water and incubated with RNAse-free DNAse (Promega, Madison, Wis.) to digest genomic DNA. RNA was extracted from DNAse using phenol/chloroform, precipitated with ethanol and resuspended in diethyl pyrocarbonate treated water. Integrity of RNA was verified following separation by electrophoresis into a 0.8% agarose gel containing formaldehyde and visualization using ethidium bromide.

[0067] Reverse-Transcription Polymerase Chain Reaction Studies

[0068] The presence of messenger RNA encoding VE-cadherin in dissected human tissue containing SC or primary cultures of SC cells was determined by RT-PCR. Utilizing Avian Myeloblastosis Virus reverse transcriptase (Boehringer Mannheim, Indianapolis, Ind.), DNA copies of total RNA were made using a primer specific for VE-cadherin (Genbank number: NM001795) antisense RNA transcripts (5′-ATCCCATTGTCTGAGATGACC-3′ (SEQ ID NO:3) or 5′-GAGGATGCAGAGTAAGATGG-3′ (SEQ ID NO:4)) as described previously (Stamer WD et al Curr Eye Res. 1995; 14:1095-1100). Amplification of RT cDNA by taq polymerase (Life Technologies) was per-formed as previously described 31 using 30 PCR cycles (94° C. for 30 s, 55° C. for 30 s and 72° C. for 90 sec). Specific amplification of VE-cadherin cDNAs was accomplished using a primer set that corresponds uniquely to VE-cadherin (sense: 5-GAATCCATTGTGCAAGTCCAC-3 or 5-ACCCCTGGTATAACCTGACT-3antisense: 5-ATCCCATTGTCTGAGATGACC-3) and PCR products were analyzed on 1.4% agarose gels. Based upon published sequence, the expected size of a VE-cadherin PCR product is 308 or 373 base pairs, depending upon the primer set used. Two different primer sets to unique VE-cadherin sequences were tested with all RNA preparations in initial screens before sequencing. As a positive control, VE-cadherin RNA was isolated from human umbilical vein endothelial cells and mRNA encoding VE-cadherin was copied and amplified as described above. Since DNA coding VE-cadherin contains no introns, we were rigorous with controls to minimize possibility of false positive amplification of genomic DNA. Negative controls include: the exclusion of cDNA from PCR (water control), treatment of RNA with RNAse-A prior to RT reaction and the inclusion of RNA not reversed transcribed in the PCR reaction. To verify the identity of PCR-generated DNA, all of the products were sequenced in both directions.

[0069] Western Blot Analysis

[0070] Equivalent protein from sodium dodecyl sulfate (SDS) solubilized whole cell lysates containing 5% β-mercaptoethanol were electrophoresed into 7.5% polyacrylamide gels containing 0.1% SDS. Fractionated proteins were blotted onto nitrocellulose using the Transblot system as per manufacturer instructions (Biorad, Hercules, Calif.). The blots were preincubated for 30 minutes at 22° C. in Tris-buffered saline (25 mM Tris and 150 mM NaCl) containing 5% nonfat powdered milk and 0.2% Tween-20 (TBS-T), and were then probed with appropriate antibodies for 2 hr at 22° C. The blots were washed (3×15 min) in TBS-T and were incubated for 2 hours with horseradish peroxidase-conjugated secondary antibodies (goat anti-mouse, 1:5000, Pierce). The blots were washed (3×15 min) in TBS-T and specific labeling was visualized following enhanced chemiluminescence (Pierce, Rockford, Ill.) and exposure (10 seconds) to ECL-Hyperfilm (Amersham, Arlington Heights, Ill.). Immunoblots were digitized using the UVP gel documentation system and densitometry was performed using LabWorks software (Upland, Calif.).

[0071] Results

[0072] To identify the different cadherin subtypes expressed in human SC cells, cadherin cDNAs were amplified by RT-PCR using degenerate oligonucleotide primers that correspond to well-conserved amino acid sequences of the cadherin cytoplasmic domain (Suzuki S et al

[0073] Cell Regulation. 1991;2:261-270). A cDNA band of approximately 150 bp was amplified from two different SC cell strains, gel purified, subcloned into an expression vector and bacteria were trans-formed. Ninety-six individual bacterial clones were selected and grown in a microtiter plate and DNA from each well was transferred to nitrocellulose. Southern blot analysis using a radiolabeled probe that specifically hybridizes to N-cadherin (cadherin-2) revealed that ˜45% of total clones were of the N-cadherin type (Table 1). Since N-cadherin commonly is co-expressed with VE-cadherin, the remaining clones were screened by PCR using primers that correspond uniquely to VE-cadherin (Navarro et al J Cell Biol. 1998;140:1475-1484). Approximately one third of the clones that did not hybridize to N-cadherin, (19% of total) were VE-cadherin (Table 1). TABLE 1 Summary of cadherin expression in SC cells SC3 SC7 SC SUMMARY N-CADHERIN 42% 48% 45% (20/48) (23/48) (43/96) VE-CADHERIN 24%* 18%* 19%** OTHER*** 34% 34% 36%

[0074] In order to characterize the expression of VE-cadherin in SC cells, a monoclonal antibody against VE-cadherin was first examined in bovine retinal vessels in whole mount by indirect immunofluorescence microscopy and a variety of endothelial cell lines were analyzed using western blot. Using retinas prepared by whole mount, FIGS. 1A-B shows a pattern of immunoreactivity in retinal vascular endothelium characteristic of VE-cadherin. Thus, reactivity was limited to cell-cell borders and to the vascular structures of the retina. This same pattern of reactivity was observed at borders between bovine retinal endothelial cells in culture (FIG. 1C). To verify specificity of anti-VE-cadherin IgG, whole cell lysates from bovine retinal endothelial cells, bovine aortic endothelial cells, human umbilical vascular endothelial cells, human iliac endothelial cells, rat smooth muscle cells and human smooth muscle cells were analyzed by western blot (FIG. 1D). Antibodies reacted uniquely to a single protein species at approximately 130 kd, that corresponds to the predicted molecular weight of VE-cadherin. Anti-VE-cadherin antibodies were next used in western blots that analyzed tissue preparations containing SC cells. Outflow tissues containing SC vessels were microdissected from human donor eyes and were solublized in 2% SDS. Lane 2 of FIG. 2 (SC/TM) demonstrates the presence of a protein in SC cell lysates that specifically reacts as a single band with anti-VE-cadherin IgG. This protein co-migrates with an immunoreactive protein contained in bovine aortic endothelial cells (BAEC, positive control, lane 1) at about 130 kd. We also analyzed primary cultures of TM cells (TM, lane 3) and were unable to detect VE-cadherin protein expression by these methods. Blots were stripped of antibody complexes and incubated with antibodies specific for PECAM-1 and β-catenin. Results show that β-catenin was expressed in all samples; however, PECAM-1 was only detected in the SC preparations. To visualize the location of VE-cadherin immunoreactivity observed in outflow tissue preparations by western blot, frozen sections containing SC and TM were analyzed by indirect immunofluorescence microscopy. Using wedges of tissue prepared from anterior chambers of human eye bank eyes, we examined the expression of VE-cadherin and observed specific labeling of VE-cadherin of both inner and outer wall cells of SC (FIG. 3, panel A-B). With respect to outflow structures, the labeling was limited to endothelial cells of SC and collector channels (internal positive control, inset panel F); no labeling above background was observed in the trabecular meshwork. Labeling of SC cells was characteristic of VE-cadherin and was limited to cell borders (inset panel B). We failed to see specific labeling of cornea endothelium, cornea epithelium, ciliary muscle, scleral fibroblasts and stromal fibroblasts. A similar labeling pattern was observed using antibodies against another protein that participates in adherens junctions, platelet endothelial-cell adhesion molecule-1 (PECAM-1). Panels C-D show specificimmunoreactivity of SC endothelium. The trabecular mesh-work and other surrounding structures did not bind anti-PECAM-1 IgG. Panels E-F are included to demonstrate the background fluorescence and autofluorescence of anterior chamber structures under the conditions of the present experiments. To confirm independently the findings from studies using immunofluorescence microscopy and cDNA screens, RT-PCR was used with total RNA isolated from dissected tissues containing SC (SC/TM) and primary cultures of SC cells (SC) isolated specifically from human eye bank eyes. Reverse transcription was performed using total RNA isolated from outflow tissues dissected bluntly from human anterior chambers, cultured human SC cells or human umbilical vein endothelial cells; and PCR was used to amplify resulting cDNAs. With primers specific for human VE-cadherin, a single PCR product was obtained using cDNAs prepared from either human source containing SC cells (FIG. 4, lanes 1). Depending upon the primer set used, DNA products obtained (panel A 308 bp or panel B 373 bp) were the same size as those obtained using cDNA prepared from human umbilical vein endothelial cells (HUVEC, lane 1, positive control). Such PCR products were not acquired when the RNAs were treated with RNase (lanes 2) prior to RT or when cDNA was omitted from the PCR (water control, lanes 3). PCR products were sequenced and found to correspond identically to VE-cadherin.

[0075] These data demonstrate the expression of two proteins that participate in adherens junctions at borders between SC cells. PECAM-1 (CD31) protein and VE-cadherin messenger RNA and protein were expressed in SC but not trabecular meshwork cells. The significance of this report is three fold. First, it provides unambiguous data that SC cells are vascular in origin. Second, it provides the first useful markers to distinguish TM from SC cells. Third, it implicates adherens junctions as sites for regulation of resistance to aqueous humor outflow. While SC is formed from intrascleral venous plexus and SC cells contain structures that resemble Weibel-Palade bodies, immunochemical confirmation of putative endothelial nature of SC has been ambiguous. For example, SC cells reacted weakly, in patches or not at all to antibodies against an endothelial marker protein, von Willebrand factor (Wang N et al Nature Med. 2001 ;7:304-309; Stamer WD et al Invest Ophthalmol Vis Sci. 1998;39:1804-1812; Hamanaka T et al Exp Eye Res. 1992;55:479-488; Pandolfi M. Archiv Ophthalmol. 1976;94:656-658). In the present study we examined the expression of two alternative endothelial-specific proteins and demonstrated that SC cells exclusively express VE-cadherin and PECAM-1 in the conventional human outflow pathway. Our findings of PECAM-1 expression in SC extend data presented previously (Wang N et al Nature Med. 2001 ;7:304-309). Since SC cells express two proteins that contribute to permeability of vascular endothelium, we hypothesize that adherens junctions between SC cells contribute to resistance of aqueous outflow. Approximately 90% of the transendothelial solute exchange in the vascular system occurs paracellularly, regulated in part by VE-cadherin and associated proteins (Corada Met al Proc Natl Acad Sci USA. 1999;96:9815-9820; Wong R et al Am J Physiol. 999;276:H736 H748; Haselton F, Heimark R J Cell Physiol. 1997;171: 243-251). For example, monoclonal antibodies directed at extracellular domains of VE-cadherin inhibit junction formation and dramatically increase permeability of endothelial monolayers (Haselton F, Heimark R J Cell Physiol. 1997; 171: 243-251; Corada M, et al Blood. 2001;97:1679-1684). Additionally, a variety of stimuli that affect the rearrangement of cytoskeletal proteins at the level of adherens junctions increase permeability of endothelial monolayers (Bazzoni G, Dejana E. Microcirculation. 2001;8:143-152). For example, inactivation of Rho members of the Ras superfamily of small GTP-binding proteins disrupted the barrier function of endothelial monolayers (Bazzoni G, Dejana E. Microcirculation. 2001;8:143-152). Rho family members are key players in the signal transduction mecha-nisms that regulate a diverse range of intracellular activities such as the formation of actin stress fibers, lamellipodia, filopodia, as well as a number of intracellular tyrosine and serine/threonine kinases (Fukata M, Kaibuchi K. Nat Rev Mol Cell Biol. 2001 ;2:887-897).With respect to SC endothelia, disruption of actin cytoarchetecture or inhibition of rho GTPase results in increased outflow facility or permeability of SC monolayers (Kaufmnan P Invest Ophthalmol Vis Sci. 1982;23:64650; Honjo M, et al Invest Ophthalmol Vis Sci. 2001;42:137-144; Rao P Invest Ophthalmol Vis Sci. 2001;42:1029-1037). Interestingly, effects of these drugs on vascular endothelia and SC endothelia are similar even though direction of flow across vascular endothelia is opposite that of flow across inner wall of SC. In addition to expressing identical adherens junction proteins at cell borders, SC cells and vascular endothelia both appear to utilize similar intercellular signaling pathways that regulate paracellular permeability. For example, SC cells express the endothelial-specific nitric oxide synthase (eNOS) (Nathanson J, McKee M. Invest Ophthalmol Vis Sci. 1995;36:1765-1773) and activation of this enzyme by nitric oxide-mimicking vasodilators decrease outflow resistance (Schuman J, et al Exp Eye Res. 1994;58:99-105). In contrast, some signaling pathways that control vascular permeability appear to be different between vascular endothelia and SC cells. For example, venous endothelium in the eye express vascular endothelial growth factor (VEGFR)3 and endothelium of the microvasculature express VEGFR1 and VEGFR2, however there is currently no evidence that any of the receptors for VEGF are expressed in SC cells (Yamaguchi T et al Development.1993;1 18:489-498; Kim I, et al Invest Ophthalmol Vis Sci. 1999;40:2115-2121; Kubo H, et al Proc Natl Acad Sci USA. 2002;99:8868-8873).

[0076] The importance of cell-cell adhesion at the level of SC in aqueous outflow facility has been suggested by several studies using a variety of compounds that are known to affect cell-cell junctions (Bill A, Invest Ophthalmol Vis Sci. 1980;19:492-504; Epstein D L, et al Invest Ophthalmol Vis Sci. 1987;28:2067-2075; Liang L-L, et al Arch Ophthalmol. 1992;1 10: 106-109; Tian B, et al Arch Ophthalmol. 1998;1 16:633-643; Peterson J, et al Invest Ophthalmol Vis Sci.1999:931-941). These compounds disrupted cell-cell junctions and increased aqueous outflow. Conversely, others have shown that compounds that specifically target and occlude intercellular junctions of SC decrease outflow facility (Ethier C, et al Invest Ophthalmol Vis Sci. 2001 ;42: 1795-1802).The regulated involvement of cell-cell junctions in aqueous outflow function was implicated using two different approaches. First, Freddo and colleagues have demonstrated that the complexity of cell-cell junctions in SC of human eyes decreased (became more labile) in response to increased intraocular pressure (Ye W, et al Invest Ophthalmol Vis Sci. 1997;38:2460-2468).These data for the first time implicated cell-cell junctions as a mechanism by which outflow cells respond to flow/pressure. Second, Alvarado and colleagues have shown that adrenergic agents may regulate the permeability of outflow cell monolayers (Alvarado J A, Invest Ophthalmol Vis Sci. 1998;39:1813-1822). For example, epinephrine increased paracellular spaces between TM and SC cells and increased cellular permeability to water in an in vitro model. Using this same approach, it has been shown that the intercellular-signaling molecule, cAMP, is affected by flow/pressure in SC cells; a response that required intact, mature cell-cell junctions (Stamer W et al Invest Ophthalmol Vis Sci. 1999;40:1983-1988).Taken together, the above data support that cell-cell junctions in the conventional outflow pathway of the human eye participate in the regulation of aqueous outflow resistance thereby providing a cellular pathway of potential targets for future glaucoma therapy. Pharmacological interference with the delivery to or turnover of adherens proteins at the cell surface may decrease adhesive strength between SC cells. Thus, weakening of adheren-mediated adhesive interactions between cells of the inner wall of SC can increase outflow facility.

Example 2

[0077] The purpose of the following experiments was to test the effects of Na₂EDTA in vivo at the level of SC and that disruption/reformation of cell-cell junctions at level of SC represent a likely mechanism for outflow tissues to respond to transient changes in pressure.

[0078] Materials and Methods

[0079] Cell Types and Culture

[0080] SC Cells: Human cadaveric eye tissue was obtained from Donor Network of Arizona, San Diego Lions Eye Bank or North Carolina Lions Eye Bank within 48 hours of death for whole eyes stored in moist chambers, and within 96 hours for non-transplantable corneal anterior segments stored in Optisol (Chiron Vision, Clairmont, Calif.). Human SC cells were isolated from the cadaveric eye tissue using gelatin-coated cannulas, as described previously (Stamer WE, et al Invest Ophthalmol Vis Sci 1998;39:1804-1812) or by differential dissection (O'Brien E, Invest. Ophthalmol. Vis. Sci. 2000;41 :3842-3849). Cells used in perfusion studies were isolated by both methods while only cells isolated by differential dissection were used in morphology experiments. Cells were grown and maintained in Dulbecco's Modified Eagle Medium (DMEM) and maintained in humidified air containing 5% CO₂ at 37° C., as described previously (Stamer WD, et al Invest Ophthalmol Vis Sci 1998;39:1804-1812). Human SC cells were seeded at 100,000 cells/cm² onto 1-cm² Snapwell Filters (Snapwell; Costar, Acton, Mass.) with 0.4-μm pore diameter in 10% FBS/DMEM. Primary cultures of eight SC cell strains were isolated from eight different cadaveric eyes without a history of glaucoma and used in the present study (SC3, SC6, SC10, SC11, SC41, SC42, SC 57 and SC68).

[0081] MDCK Cells: Madin-Darby Canine Kidney cells (MDCK), were used as a control to characterize perfusion system and for comparisons to SC monolayers. Responses of calcium-sensitive junctional complexes between MDCK cells are well documented (Nelson J Cell Biol 1987;104:1527-1537) and were the most consistent in preliminary feasibility experiments that evaluated the resolution of the perfusion system to changes in TEER and HC (compared to bovine aortic endothelial cells and calf pulmonary aortic endothelial cells). MDCK cells thus served as a positive control for comparisons with SC cells in subsequent experiments. MDCK Cells used in the present study were a gift from Dr. Ronald Lynch (University of Arizona) and were used between passages 14-16. Cells were grown in DMEM and maintained in humidified air containing 5% CO2 at 37° C. for at least three weeks after reaching confluence before experimentation. Cells that were past five weeks post-confluence were not used because HC and TEER were not responsive to EDTA during the time course of the experiments.

[0082] Measurement of Transendothelial Electrical Resistance and Hydraulic Conductivity

[0083] Transendothelial electrical resistance (TEER) of cell monolayers cultured on Snapwell filters was measured using a TEER measurement chamber (ENDOHM-24; World Precision Instruments) in conjunction with an epithelial voltohmmeter (EVOM; World Precision Instruments). Following three rinses with prewarmed 20 mM HEPES (Sigrna, St. Louis, Mo.) buffered DMEM (serum-free, pH 7.4; HEPES-DMEM), filters were carefully transferred to the TEER measurement chamber filled with HEPES-DMEM. The background electrical resistance of medium and insert was measured (typically 12-13 Ω cm²) and subtracted from measurements of filters with cells in medium. Cell monolayers were excluded from the present study if they did not exhibit mature intercellular junctional complexes, as evidenced by a minimum net TEER of 10 Ω cm² after three weeks at confluence. We chose this level of maturity because monolayers less resistive consistently failed to withstand control chamber exchanges and/or pressure gradients of 5 mmHg. Further, cell monolayers cultured on filters greater than five weeks had greater TEER, but consistently lifted off of filters during control chamber exchanges. Based upon experience with human umbilical and bovine aortic endothelial cells on similar filters, weak adherence was likely the result of cells having of a greater reliance on cell-cell associations rather than cell-matrix associations over time (Ronald Heimark, personal communication). The Snapwell filters containing the cell monolayers were then carefully placed into an Ussing-type chamber (Ussing system CHM5; World Precision Instruments, Sarasota, Fla.) filled with HEPES-DMEM and maintained at 37° C. in an air incubator for 15 minutes prior to pressure application. Filters were oriented such that the apical surface of cell monolayers faced the upstream chamber. Flow through cell monolayers was a function of the pressure gradient between the upstream and downstream compartments of the chamber. Pressure in the upstream compartment was generated by an elevated reservoir of HEPES-DMEM, with pressure recorded using a pressure transducer (AH 60-3002; Harvard Apparatus, Holliston, Mass.), while the downstream compartment was vented to atmospheric pressure. The rate of fluid flow through the chamber was calculated from the weight change per unit time of the reservoir measured using an isometric transducer (AH 60-2994; Harvard Apparatus). Pressure and weight data were recorded simultaneously at 30 times/sec onto hard drive of computer using a Data Acquisition System (MP100WSW; Biopac Systems, Inc., Santa Barbara, Calif.).

[0084] Simultaneously, TEER was recorded manually at fixed intervals using the epithelial voltohmmeter and 3M KCl-filled electrodes (DRIREF-L; WPI) positioned in measurement ports on either side of cell monolayers in the Ussing-type chamber. Cell monolayers were excluded if they did not exhibit 15 minutes of stable TEER measurement prior to exposure to pressure.

[0085] Once stable TEER was achieved, a valve between the reservoir and chamber was opened to expose the upstream chamber to pressure. TEER, flow, and pressure measurements were recorded for 20 minutes to establish baseline values. Cell monolayers were excluded if the flow rate was greater than 30 ml/min or increased dramatically between the baseline measurements, indicating a compromised cell monolayer. The medium in the upstream chamber was then exchanged with 5.0 αL HEPES-DMEM at a rate of 2.5 m/min, and a second 10-minute baseline period was measured. An upstream chamber exchange using 5.0 ml of Na₂EDTA in HEPES-DMEM was then performed, followed by a five-minute measurement period during which TEER was measured once per minute. The upstream chamber was then rinsed with 5.0 ml HEPES-DMEM, and TEER was measured once per minute until no change was observed for three successive measurements. Hydraulic conductivity was measured continuously and TEER measurements were then taken every five minutes for the duration of the trial. Following completion of TEER and hydraulic conductivity measurements, TEER of cell monolayers was measured using a TEER measurement chamber for comparison with pre-trial TEER.

[0086] Calculation of Hydraulic Conductivity

[0087] Hydraulic conductivity was calculated in real time by Biopac data acquisition software using pressure and flow measurements. The formula used to compute hydraulic conductivity was:

HC=Q/(P*A)

[0088] Where Q is the volumetric flow rate across cell monolayers. αL/min), P is pressure (mmHg), and A is the area of a Snapwell filter (1.13 cm²).

[0089] Since pressure and area are constant in the experimental paradigm, HC is dependent upon Q. Pressure applied to the monolayer is contingent upon the height of a reservoir that empties as fluid moves across cell monolayers. The initial pressure for all experiments is 6 mmHg and decreases gradually during the experiment. Q is calculated from change in weight of column of fluid over time.

[0090] SC Monolayer Morphology

[0091] Images were taken from a time-lapse video recording of SC or MDCK cells just before and after the flow of buffered 10 mM Na₂EDTA reduced the extracellular calcium concentration. A 25× phase contrast objective, 4× relay magnification, real time noise reduction and contrast enhancement, Dage videocamera and a 36° microscope chamber allowed us to visualize cell responses to calcium removal in real time. A flow chamber allowed the rapid exchange of buffer medium with or without EDTA with only a brief (5-8 sec) loss of imaging. The microscope was enclosed in an insulated chamber and warmed to a constant 36° with infrared heat lamps.

[0092] The initial image was obtained with a Dage Newvicon video camera, and then processed to remove noise and to increase contrast using a Hamamatsu real time image processing system (Argus 10). The limit of resolution for this technique was ˜300 nm. Images were then stored on a Panasonic time-lapse video recorder at about a 60-fold time-lapse factor.

[0093] Statistical Analyses

[0094] Paired t-tests were used to compare rate of TEER change during the baseline measurement period versus rate of TEER change during Na₂EDTA treatment for SC cell monolayers and for MDCK cell monolayers. A paired t-test was also used to determine whether the percent change between the baseline measurement of HC (mean of two measurements) and the measurement of HC following Na₂EDTA treatment was greater than the percent change in HC between the first and second baseline measurements. Similarly, a paired t-test was used to determine whether the percent change between the baseline measurement of HC (mean of two measurements) and the measurement of HC following washout of Na₂EDTA was greater than the percent change in HC between the first and second baseline measurements.

[0095] Results

[0096] Preliminary experiments were conducted to optimize the measurement of Na₂EDTA effects and pressure gradients on cell monolayers. Titration experiments revealed that a that a minimum of 25 mM Na₂EDTA was required to effect both hydraulic conductivity and TEER of MDCK cell monolayers in the time course of the experiments, while only 5 mM Na₂EDTA was needed for SC monolayers (n=13-15, data not shown). Lower concentrations of Na₂EDTA were tested (0.5-2 mM) and found not to impact significantly HC or TEER of SC monolayers in the time course of the experiment (n=6). The optimal amount of time that was required to observe consistent changes was 5 minutes. The optimal range of pressure differentials across cell monolayers to resolve changes in hydraulic conductivity was 14-16 mmHg for MDCK and 4-6 mm Hg for SC. Higher pressures for each cell type consistently compromised integrity of cell monolayers and produced erratic data (n=5-8).

[0097] TEER Effects Hydrostatic Pressure Gradients

[0098] The effects of hydrostatic pressure gradients (4-6 mm Hg for SC and 14-16 mm Hg for MDCK) on TEER were analyzed and compared. As shown in FIG. 5, TEER in both SC and MDCK cell monolayers was stable at atmospheric pressure. Upon exposure to a hydrostatic pressure gradient, TEER in both cell monolayers decreased. FIG. 2a shows average TEER changes for both SC and MDCK cell monolayers during a 30-minute measurement period. TEER of SC cell monolayers decreased at an average rate of 0.24 (±0.05 SEM) Ω cm²/min (n=5) while TEER of MDCK cell monolayers decreased at a rate of 0.3 (±0.12 SEM) Ω/min (n=4). TEER changes due to exposure to hydrostatic pressure for both SC and MDCK cell monolayers were significantly different from baseline TEER measurements taken in the absence of pressure (p<0.05).

[0099] TEER Effects of Na₂EDTA

[0100] Exchange of chamber with normal medium did not affect rate of TEER change. However, after Na₂EDTA treatment, TEER decreased at a new average rate of 1.9 (±0.12 SEM) Ω cm² /min (n=4) in MDCK cell monolayers and 0.34 (±0.26 SEM) Ωcm² /min (n=5) in SC cell monolayers (FIGS. 5 and 6b). FIG. 5 shows effect of Na₂EDTA relative to other treatments and 2 b shows histogram of net average TEER changes for both SC and MDCK cell monolayers after Na₂EDTA treatment. Paired t-tests showed no significant change in TEER decrease for SC cell monolayers relative to the 30-minute baseline measurement period in the presence of pressure. In contrast, MDCK cell monolayers showed a change in TEER that approached significance (p=0.06). Following rinse with normal medium, average rate of change of TEER for both SC and MDCK cell monolayers returned to levels not significantly different from pre-Na₂EDTA rates for the duration of the testing period.

[0101] Effects of Na₂EDTA on Hydraulic Conductivity

[0102]FIG. 7 shows values from individual experiments comparing hydraulic conductivity before (baseline), during (EDTA), and after (rinse) treatment with Na₂EDTA. SC cell monolayers were exposed to 5 mM Na₂EDTA (driven by 4-6 mm Hg gradient), while MDCK cell monolayers were exposed to 25 mM Na₂EDTA (driven by 14-16 mm Hg gradient) for 5 minutes.

[0103] During the 30-minute baseline measurement period, MDCK cell monolayers exhibited an average stable hydraulic conductivity of 0.038 ed/min/mmHg/cm 2, compared to 2.44 μl/mmHg/cm 2 in SC cell monolayers. This level is consistent with permeability measurements from SC monolayers in vitro by others and about 10-fold greater than calculated in vivo (Underwood J, et al Am J Physiol 1999;277:C330-C342; Alvarado J A, et al Invest Ophthalmol Vis Sci 1998;39:1813-1822; Johnson M, Erickson K. Mechanisms and routes of aqueous humor drainage. In:Albert D, Jakobiec F, eds. Principles and practice of ophthalmology. Philadelphia: W B Saunders Co., 2000:2577-2595). As expected, baseline HC measurements were dependent upon initial TEER measurement for monolayer (table 1). Following a 5-minute Na₂EDTA treatment, hydraulic conductivity of the five SC cell monolayers from four different cell strains tested increased 68%, 94%, 116%, 119%, and 230% relative to baseline. Hydraulic conductivity of the four MDCK monolayers increased 128%, 285%, 1664%, and 346% relative to baseline. Following chamber exchange with normal medium, hydraulic conductivity of SC cell monolayers continued to increase (123%, 156%, 406%, 505%, and 454%) relative to baseline, while MDCK cell monolayers exhibited a decrease in hydraulic conductivity to 17%, −35%, 1137%, and 12% relative to baseline during the 15 minute baseline period (table 1). In two additional experiments with SC monolayers, HC was examined two hours after Na₂EDTA challenge in the presence of a pressure gradient and found to return to near baseline levels (58% and −39% relative to baseline).

[0104] Percent change in HC relative to baseline following Na₂EDTA treatment was significantly greater than percent change of HC between the two baseline measurements in SC cells (p<0.05) and in MDCK cells (p<0.05). Percent change in HC relative to baseline following post-Na₂EDTA rinse with normal medium was significantly greater than percent change between the two baseline measurements in SC cells (p<0.05) but not in MDCK cells. TABLE 1 Hydraulic conductivity measurements of cell monolayers Cell Line Net TEER Baseline HC Post-EDTA HC Post-Rinse HC SC 10 10 5.79 10.79 14.22 SC 10 15 0.47 0.95 2.63 SC 11 10 5.25 18.14 30.44 SC 41 14 0.008 0.18 0.42 SC 43 12 0.61 1.02 1.36 MDCK 76 0.053 0.12 0.062 MDCK 78 0.058 0.22 0.038 MDCK 64 0.0062 0.11 0.077 MDCK 53 0.034 0.15 0.038

[0105] Morphological Effects of Na₂EDTA

[0106] In parallel experiments, effects of Na₂EDTA on cell margins were visualized en face using phase-contrast videomicroscopy on glass coverslips. FIG. 8 shows still images captured from video sequences of live SC cell monolayers before and after Na₂EDTA treatment. Panel A shows the edge of 2 adjacent SC cells before exposure to Na₂EDTA. The tips of the arrows show the margins of the cells. The cell margins appeared to be touching to the left of arrows, and were slightly separated (<0.5 αm) at the arrows. Separations like this were uncommon, however these areas were chosen to image because it enabled locating and tracking of cell borders during the experiment. Panels B and C show the same field of view 60 and 90 seconds after the addition of Na₂EDTA. The cell margins retracted about 2 μm from each other in B, and about 3 μm in C. Fine “retraction fibers” are evident in the developing space between cell margins. MDCK cell monolayers were also evaluated before and after Na₂EDTA treatment. MDCK cell borders retracted from a belt-like arrangement of fibers near, but off the basal surface of the cells by 60 seconds (data not shown).

[0107] Consistent with perfusion studies, cell margins that retracted as a result of exposure to Na₂EDTA did not immediately come back together upon removal of Na₂EDTA. In fact, when exposed to 10 mM Na₂EDTA for 5 minutes, about 30 minutes were required for the margins of the cells return to their original position after replacement of normal medium (data not shown). By time lapse, the cells appeared to follow the retraction fibers left behind during retraction (data not shown).

[0108] Discussion

[0109] These data show that permeability of cultured human SC cells respond to physiologically relevant hydrostatic pressure gradients and to the calcium chelator, Na₂EDTA in a manner similar to that previously observed in situ (Ye W, et al Invest Ophthalmol Vis Sci 1997;38:2460-2468) and in vivo, respectively (Warner D, Chu E. Can. J Ophthalmol. 1967;2:226. Bill A, et al Invest Ophthalmol Vis Sci 1980;19:492-504). In cultured SC cell monolayers, transendothelial electrical resistance significantly decreased in response to hydrostatic pressure, and hydraulic conductivity significantly increased in response to Na₂EDTA. These data show that calcium-sensitive intercellular junctions of Schlemm's Canal contribute in part to the generation of resistance for aqueous humor outflow and may serve to relieve transient increases in intraocular pressure. Previous research has shown that complexity of intercellular junctions between inner wall cells of Schlemm's Canal (as indicated by fewer tight junctional strands) decreases in response to elevated pressure (Ye W, et al Invest Ophthalmol Vis Sci 1997;38:2460-2468). Effect of pressure gradients of 0 (atmospheric), 15 and 45 mmHg were assessed. In the present study, a hydraulic pressure gradient of 5 mm Hg was evaluated and found to significantly decrease transendothelial electrical resistance (TEER) measurements across SC cell monolayers. Since TEER is an indicator of junctional complexity between cells, these functional in vitro results are consistent with those found morphologically in situ. Such rapid changes in junctional complexity may occur in combination with increased giant vacuole formation serve to accommodate transient changes in intraocular pressure that occur routinely due to eye rubbing or ocular pulsations (Johnstone M, et al Am J Ophthalmol 1973;75:365-383; Grierson I, Lee W. Exp. Eye Res. 1974;19:21-33). While pressure-dependent changes in giant vacuoles are well documented, data indicate that pore density of inner wall cells is not pressure-dependent (Ethier C. Exp. Eye. Res. 2002;74:161-172.). This suggests that intercellular pores contribute to the long-term permeability of the inner wall while complexity of intercellular junctions and/or formation of vacuoles may contribute to short-term adaptations.

[0110] Chelation of calcium has been shown to increase aqueous humor outflow facility in vivo in two different animal models (Warner D, Chu E. Can. J Ophthalmol. 1967;2:226; Bill A, et al Invest Ophthalmol Vis Sci 1980;19:492-504; Hamanaka T, Bill A. Exp Eye Res 1987;44:171-190). The concentration of Na₂EDTA used with SC monolayers in the present study (0.5-10 mM) was consistent with that used in these studies (0.5-6 mM) and with the theoretical concentration needed to buffer calcium in perfusion medium (2.0 mM) plus provide a sufficient gradient to pull calcium out from intercellular junctions. The present study tested whether the effects that have been observed in vivo are present at the level of SC. The results showed that chelation of calcium by Na₂EDTA significantly increased hydraulic conductivity across SC cell monolayers, presumably by ligating intercellular junctions. In addition, morphological findings showed a noticeable separation of cell-cell associations following Na₂EDTA treatment, consistent with a decrease in complexity of cell-cell junctions. Given the hydraulic conductivity and morphological findings, a corresponding decrease in TEER following Na₂EDTA treatment was expected, but not measured. Failure to detect a consistent and significant change in TEER after Na₂EDTA treatment in SC cell monolayers may have been the result of the initial pressure-driven decrease in junctional complexity, which reduced TEER to a level (basement effect) where further TEER decreases cannot be resolved.

[0111] Increases in aqueous humor outflow due to calcium chelating agents have been shown to be reversible in vivo (Warner D, Chu E. Can. J. Ophthalmol. 1967;2:226; Bill A, et al Invest Ophthalmol Vis Sci 1980;19:492-504). In perfusion experiments, MDCK cell monolayers exhibited a partial recovery of TEER and hydraulic conductivity shortly after washout of Na₂EDTA. In contrast, hydraulic conductivity of SC cell monolayers took longer to approach baseline levels following washout of Na₂EDTA. To examine this further, we followed SC monolayers after washout of Na₂EDTA for longer periods of time by Video microscopy and noticed that about 30 minutes were required for cell-cell contacts to begin to return visually and 2 hours functionally via TEER measurements. The differences in recovery between MDCK (seconds) to SC (minutes to hours) are likely related to respective differences between MDCK and SC in initial junctional complexity (60 versus 28 Ω cm²), hydraulic conductivity (2.44 versus 0.038 αl/min/mmHg/cm ²) and effects of cell culture on the ability to form mature intercellular junctions. The differences observed between these two cell types likely reflect differing roles in vivo.

[0112] In conclusion, these data using cultured SC monolayers a) are similar to previous data using intact outflow pathways and b) are consistent with the idea that calcium-sensitive intercellular junctions between Schlemm's Canal cells are likely sites of action of hydrostatic pressure gradients, Na₂EDTA and other calcium chelators. The recent documentation of the unique expression of vascular endothelial cadherin in human Schlemm's canal cells but not trabecular meshwork cells in the human outflow pathway may explain these results (Heimark et al Curr Eye Res 2002;25:299-308). Vascular endothelial cadherin is an endothelial-specific, calcium-sensitive intercellular junction protein that in part mediates permeability of vascular endothelium ( Corada M, et al Proc. Natl. Acad. Sci. USA 1999;96:9815-9820) and now represents a future therapeutic target for regulation of aqueous humor outflow in people with glaucoma. The demonstration that the experimental model described herein can detect small changes in hydraulic conductivity and transendothelial electrical resistance supports the usefulness of this model in examining efficacy of drugs that can interact with vascular endothelial cadherin or other potential targets in SC cell monolayers.

[0113] Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

1 8 1 26 DNA Artificial Sequence synthetic oligonucleotide 1 aatgaattcg tnttygayta ygargg 26 2 27 DNA Artificial Sequence synthetic oligonucleotide 2 aatgaattcr tcngcnagyt tyttraa 27 3 21 DNA Artificial Sequence synthetic oligonucleotide 3 atcccattgt ctgagatgac c 21 4 20 DNA Artificial Sequence synthetic oligonucleotide 4 gaggatgcag agtaagatgg 20 5 2853 DNA Homo sapiens 5 accctggccg ctgttggtgc tgccgctgcc tcctcctcct ccgccgccgc cgccgccgcc 60 gccgcctcct ccggctcttc gctcggcccc tctccgcctc catgtgccgg atagcgggag 120 cgctgcggac cctgctgccg ctgctgctgg ccctgcttca ggcgtctgta gaggcttctg 180 gtgaaatcgc attatgcaag actggatttc ctgaagatgt ttacagtgca gtcttatcga 240 aggatgtgca tgaaggacag cctcttctca atgtgaagtt tagcaactgc aatggaaaaa 300 gaaaagtaca atatgagagc agtgagcctg cagattttaa ggtggatgaa gatggcatgg 360 tgtatgccgt gagaagcttt ccactctctt ctgagcatgc caagttcctg atatatgccc 420 aagacaaaga gacccaggaa aagtggcaag tggcagtaaa attgagcctg aagccaacct 480 taactgagga gtcagtgaag gagtcagcag aagttgaaga aatagtgttc ccaagacaat 540 tcagtaagca cagtggccac ctacaaaggc agaagagaga ctgggtcatc cctccaatca 600 acttgccaga aaactccagg ggaccttttc ctcaagagct tgtcaggatc aggtctgata 660 gagataaaaa cctttcactg cggtacactg taactgggcc aggagctgac cagcctccaa 720 ctggtatctt cattatcaac cccatctcgg gtcagctgtc ggtgacaaag cccctggatc 780 gcgagcagat agcccggttt catttgaggg cacatgcagt agatattaat ggaaatcaag 840 tggagaaccc cattgacatt gtcatcaatg ttattgacat gaatgacaac agacctgagt 900 tcttacacca ggtttggaat gggacagttc ctgagggatc aaagcctgga acatatgtga 960 tgaccgtaac agcaattgat gctgacgatc ccaatgccct caatgggatg ttgaggtaca 1020 gaatcgtgtc tcaggctcca agcacccctt cacccaacat gtttacaatc aacaatgaga 1080 ctggtgacat catcacagtg gcagctggac ttgatcgaga aaaagtgcaa cagtatacgt 1140 taataattca agctacagac atggaaggaa tccccacata tggcctttca aacacagcca 1200 cggccgtcat cacagtgaca gatgtcaatg acaatcctcc agagtttact gccatgacgt 1260 tttatggtga agttcctgag aacagggtag acatcatagt agctaatcta actgtgaccg 1320 ataaggatca accccataca ccagcctgga acgcagtgta cagaatcagt ggcggagatc 1380 ctactggacg gttcgccatc cagaccgacc caaacagcaa cgacgggtta gtcaccgtgg 1440 tcaaaccaat cgactttgaa acaaatagga tgtttgtcct tactgttgct gcagaaaatc 1500 aagtgccatt agccaaggga attcagcacc cgcctcagtc aactgcaacc gtgtctgtta 1560 cagttattga cgtaaatgaa aacccttatt ttgcccccaa tcctaagatc attcgccaag 1620 aagaagggct tcatgccggt accatgttga caacattcac tgctcaggac ccagatcgat 1680 atatgcagca aaatattaga tacactaaat tatctgatcc tgccaattgg ctaaaaatag 1740 atcctgtgaa tggacaaata actacaattg ctgttttgga ccgagaatca ccaaatgtga 1800 aaaacaatat atataatgct actttccttg cttctgacaa tggaattcct cctatgagtg 1860 gaacaggaac gctgcagatc tatttacttg atattaatga caatgcccct caagtgttac 1920 ctcaagaggc agagacttgc gaaactccag accccaattc aattaatatt acagcacttg 1980 attatgacat tgatccaaat gctggaccat ttgcttttga tcttccttta tctccagtga 2040 ctattaagag aaattggacc atcactcggc ttaatggtga ttttgctcag cttaatttaa 2100 agataaaatt tcttgaagct ggtatctatg aagttcccat cataatcaca gattcgggta 2160 atcctcccaa atcaaatatt tccatcctgc gcgtgaaggt ttgccagtgt gactccaacg 2220 gggactgcac agatgtggac aggattgtgg gtgcggggct tggcaccggt gccatcattg 2280 ccatcctgct ctgcatcatc atcctgctta tccttgtgct gatgtttgtg gtatggatga 2340 aacgccggga taaagaacgc caggccaaac aacttttaat tgatccagaa gatgatgtaa 2400 gagataatat tttaaaatat gatgaagaag gtggaggaga agaagaccag gactatgact 2460 tgagccagct gcagcagcct gacactgtgg agcctgatgc catcaagcct gtgggaatcc 2520 gacgaatgga tgaaagaccc atccacgctg agccccagta tccggtccga tctgcagccc 2580 cacaccctgg agacattggg gacttcatta atgagggcct taaagcggct gacaatgacc 2640 ccacagctcc accatatgac tccctgttag tgtttgacta tgaaggcagt ggctccactg 2700 ctgggtcctt gagctccctt aattcctcaa gtagtggtgg tgagcaggac tatgattacc 2760 tgaacgactg ggggccacgg ttcaagaaac ttgctgacat gtatggtgga ggtgatgact 2820 gaacttcagg gtgaacttgg tttttggaca agt 2853 6 906 PRT Homo sapiens 6 Met Cys Arg Ile Ala Gly Ala Leu Arg Thr Leu Leu Pro Leu Leu Leu 1 5 10 15 Ala Leu Leu Gln Ala Ser Val Glu Ala Ser Gly Glu Ile Ala Leu Cys 20 25 30 Lys Thr Gly Phe Pro Glu Asp Val Tyr Ser Ala Val Leu Ser Lys Asp 35 40 45 Val His Glu Gly Gln Pro Leu Leu Asn Val Lys Phe Ser Asn Cys Asn 50 55 60 Gly Lys Arg Lys Val Gln Tyr Glu Ser Ser Glu Pro Ala Asp Phe Lys 65 70 75 80 Val Asp Glu Asp Gly Met Val Tyr Ala Val Arg Ser Phe Pro Leu Ser 85 90 95 Ser Glu His Ala Lys Phe Leu Ile Tyr Ala Gln Asp Lys Glu Thr Gln 100 105 110 Glu Lys Trp Gln Val Ala Val Lys Leu Ser Leu Lys Pro Thr Leu Thr 115 120 125 Glu Glu Ser Val Lys Glu Ser Ala Glu Val Glu Glu Ile Val Phe Pro 130 135 140 Arg Gln Phe Ser Lys His Ser Gly His Leu Gln Arg Gln Lys Arg Asp 145 150 155 160 Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro Phe 165 170 175 Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu Ser 180 185 190 Leu Arg Tyr Thr Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr Gly 195 200 205 Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys Pro 210 215 220 Leu Asp Arg Glu Gln Ile Ala Arg Phe His Leu Arg Ala His Ala Val 225 230 235 240 Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile Asn 245 250 255 Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe Leu His Gln Val Trp 260 265 270 Asn Gly Thr Val Pro Glu Gly Ser Lys Pro Gly Thr Tyr Val Met Thr 275 280 285 Val Thr Ala Ile Asp Ala Asp Asp Pro Asn Ala Leu Asn Gly Met Leu 290 295 300 Arg Tyr Arg Ile Val Ser Gln Ala Pro Ser Thr Pro Ser Pro Asn Met 305 310 315 320 Phe Thr Ile Asn Asn Glu Thr Gly Asp Ile Ile Thr Val Ala Ala Gly 325 330 335 Leu Asp Arg Glu Lys Val Gln Gln Tyr Thr Leu Ile Ile Gln Ala Thr 340 345 350 Asp Met Glu Gly Ile Pro Thr Tyr Gly Leu Ser Asn Thr Ala Thr Ala 355 360 365 Val Ile Thr Val Thr Asp Val Asn Asp Asn Pro Pro Glu Phe Thr Ala 370 375 380 Met Thr Phe Tyr Gly Glu Val Pro Glu Asn Arg Val Asp Ile Ile Val 385 390 395 400 Ala Asn Leu Thr Val Thr Asp Lys Asp Gln Pro His Thr Pro Ala Trp 405 410 415 Asn Ala Val Tyr Arg Ile Ser Gly Gly Asp Pro Thr Gly Arg Phe Ala 420 425 430 Ile Gln Thr Asp Pro Asn Ser Asn Asp Gly Leu Val Thr Val Val Lys 435 440 445 Pro Ile Asp Phe Glu Thr Asn Arg Met Phe Val Leu Thr Val Ala Ala 450 455 460 Glu Asn Gln Val Pro Leu Ala Lys Gly Ile Gln His Pro Pro Gln Ser 465 470 475 480 Thr Ala Thr Val Ser Val Thr Val Ile Asp Val Asn Glu Asn Pro Tyr 485 490 495 Phe Ala Pro Asn Pro Lys Ile Ile Arg Gln Glu Glu Gly Leu His Ala 500 505 510 Gly Thr Met Leu Thr Thr Phe Thr Ala Gln Asp Pro Asp Arg Tyr Met 515 520 525 Gln Gln Asn Ile Arg Tyr Thr Lys Leu Ser Asp Pro Ala Asn Trp Leu 530 535 540 Lys Ile Asp Pro Val Asn Gly Gln Ile Thr Thr Ile Ala Val Leu Asp 545 550 555 560 Arg Glu Ser Pro Asn Val Lys Asn Asn Ile Tyr Asn Ala Thr Phe Leu 565 570 575 Ala Ser Asp Asn Gly Ile Pro Pro Met Ser Gly Thr Gly Thr Leu Gln 580 585 590 Ile Tyr Leu Leu Asp Ile Asn Asp Asn Ala Pro Gln Val Leu Pro Gln 595 600 605 Glu Ala Glu Thr Cys Glu Thr Pro Asp Pro Asn Ser Ile Asn Ile Thr 610 615 620 Ala Leu Asp Tyr Asp Ile Asp Pro Asn Ala Gly Pro Phe Ala Phe Asp 625 630 635 640 Leu Pro Leu Ser Pro Val Thr Ile Lys Arg Asn Trp Thr Ile Thr Arg 645 650 655 Leu Asn Gly Asp Phe Ala Gln Leu Asn Leu Lys Ile Lys Phe Leu Glu 660 665 670 Ala Gly Ile Tyr Glu Val Pro Ile Ile Ile Thr Asp Ser Gly Asn Pro 675 680 685 Pro Lys Ser Asn Ile Ser Ile Leu Arg Val Lys Val Cys Gln Cys Asp 690 695 700 Ser Asn Gly Asp Cys Thr Asp Val Asp Arg Ile Val Gly Ala Gly Leu 705 710 715 720 Gly Thr Gly Ala Ile Ile Ala Ile Leu Leu Cys Ile Ile Ile Leu Leu 725 730 735 Ile Leu Val Leu Met Phe Val Val Trp Met Lys Arg Arg Asp Lys Glu 740 745 750 Arg Gln Ala Lys Gln Leu Leu Ile Asp Pro Glu Asp Asp Val Arg Asp 755 760 765 Asn Ile Leu Lys Tyr Asp Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp 770 775 780 Tyr Asp Leu Ser Gln Leu Gln Gln Pro Asp Thr Val Glu Pro Asp Ala 785 790 795 800 Ile Lys Pro Val Gly Ile Arg Arg Met Asp Glu Arg Pro Ile His Ala 805 810 815 Glu Pro Gln Tyr Pro Val Arg Ser Ala Ala Pro His Pro Gly Asp Ile 820 825 830 Gly Asp Phe Ile Asn Glu Gly Leu Lys Ala Ala Asp Asn Asp Pro Thr 835 840 845 Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly 850 855 860 Ser Thr Ala Gly Ser Leu Ser Ser Leu Asn Ser Ser Ser Ser Gly Gly 865 870 875 880 Glu Gln Asp Tyr Asp Tyr Leu Asn Asp Trp Gly Pro Arg Phe Lys Lys 885 890 895 Leu Ala Asp Met Tyr Gly Gly Gly Asp Asp 900 905 7 3170 DNA Homo sapiens misc_feature (2523)..(2523) n is a, c, g, or t 7 ctccactcac gctcagccct ggacggacag gcagtccaac ggaacagaaa catccctcag 60 cccacaggca cgatctgttc ctcctgggaa gatgcagagg ctcatgatgc tcctcgccac 120 atcgggcgcc tgcctgggcc tgctggcagt ggcagcagtg gcagcagcag gtgctaaccc 180 tgcccaacgg gacacccaca gcctgctgcc cacccaccgg cgccaaaaga gagattggat 240 ttggaaccag atgcacattg atgaagagaa aaacacctca cttccccatc atgtaggcaa 300 gatcaagtca agcgtgagtc gcaagaatgc caagtacctg ctcaaaggag aatatgtggg 360 caaggtcttc cgggtcgatg cagagacagg agacgtgttc gccattgaga ggctggaccg 420 ggagaatatc tcagagtacc acctcactgc tgtcattgtg gacaaggaca ctggcgaaaa 480 cctggagact ccttccagct tcaccatcaa agttcatgac gtgaacgaca actggcctgt 540 gttcacgcat cggttgttca atgcgtccgt gcctgagtcg tcggctgtgg ggacctcagt 600 catctctgtg acagcagtgg atgcagacga ccccactgtg ggagaccacg cctctgtcat 660 gtaccaaatc ctgaagggga aagagtattt tgccatcgat aattctggac gtattatcac 720 aataacgaaa agcttggacc gagagaagca ggccaggtat gagatcgtgg tggaagcgcg 780 agatgcccag ggcctccggg gggactcggg cacggccacc gtgctggtca ctctgcaaga 840 catcaatgac aacttcccct tcttcaccca gaccaagtac acatttgtcg tgcctgaaga 900 cacccgtgtg ggcacctctg tgggctctct gtttgttgag gacccagatg agccccagaa 960 ccggatgacc aagtacagca tcttgcgggg cgactaccag gacgctttca ccattgagac 1020 aaaccccgcc cacaacgagg gcatcatcaa gcccatgaag cctctggatt atgaatacat 1080 ccagcaatac agcttcatag tcgaggccac agaccccacc atcgacctcc gatacatgag 1140 ccctcccgcg ggaaacagag cccaggtcat tatcaacatc acagatgtgg acgagccccc 1200 cattttccag cagcctttct accacttcca gctgaaggaa aaccagaaga agcctctgat 1260 tggcacagtg ctggccatgg accctgatgc ggctaggcat agcattggat actccatccg 1320 caggaccagt gacaagggcc agttcttccg agtcacaaaa aagggggaca tttacaatga 1380 gaaagaactg gacagagaag tctacccctg gtataacctg actgtggagg ccaaagaact 1440 ggattccact ggaaccccca caggaaaaga atccattgtg caagtccaca ttgaagtttt 1500 ggatgagaat gacaatgccc cggagtttgc caagccctac cagcccaaag tgtgtgagaa 1560 cgctgtccat ggccagctgg tcctgcagat ctccgcaata gacaaggaca taacaccacg 1620 aaacgtgaag ttcaaattca tcttgaatac tgagaacaac tttaccctca cggataatca 1680 cgataacacg gccaacatca cagtcaagta tgggcagttt gaccgggagc ataccaaggt 1740 ccacttccta cccgtggtca tctcagacaa tgggatgcca agtcgcacgg gcaccagcac 1800 gctgaccgtg gccgtgtgca agtgcaacga gcagggcgag ttcaccttct gcgaggatat 1860 ggccgcccag gtgggcgtga gcatccaggc agtggtagcc atcttactct gcatcctcac 1920 catcacagtg atcaccctgc tcatcttcct gcggcggcgg ctccggaagc aggcccgcgc 1980 gcacggcaag agcgtgccgg agatccacga gcagctggtc acctacgacg aggagggcgg 2040 cggcgagatg gacaccacca gctacgatgt gtcggtgctc aactcggtgc gccgcggcgg 2100 ggccaagccc ccgcggcccg cgctggacgc ccggccttcc ctctatgcgc aggtgcagaa 2160 gccaccgagg cacgcgcctg gggcacacgg agggcccggg gagatggcag ccatgatcga 2220 ggtgaagaag gacgaggcgg accacgacgg cgacggcccc ccctacgaca cgctgcacat 2280 ctacggctac gagggctccg agtccatagc cgagtccctc agctccctgg gcaccgactc 2340 atccgactct gacgtggatt acgacttcct taacgactgg ggacccaggt ttaagatgct 2400 ggctgagctg tacggctcgg acccccggga ggagctgctg tattaggcgg ccgaggtcac 2460 tctgggcctg gggacccaaa ccccctgcag cccaggccag tcagactcca ggcaccacag 2520 cvncadctcc aaaaatggca gtgactcccc agcccagcac cccttcctcg tgggtcccag 2580 agacctcatc agccttggga tagcaaactc caggttcctg aaatatccag gaatatatgt 2640 cagtgatgac tattctcaaa tgctggcaaa tccaggctgg tgttctgtct gggctcagac 2700 atccacataa ccctgtcacc cacagaccgc cgtctaactc aaagacttcc tctggctccc 2760 caaggctgca aagcaaaaca gactgtgttt aactgctgca gggtcttttt ctagggtccc 2820 tgaacgccct ggtaaggctg gtgaggtcct ggtgcctatc tgcctggagg caaaggcctg 2880 gacagcttga cttgtggggc aggattctct gcagcccatt cccaagggag actgaccatc 2940 atgccctctc tcgggagccc tagccctgct ccaactccat actccactcc aagtgcccca 3000 ccactcccca acccctctcc aggcctgtca agagggagga aggggcccca tggcagctcc 3060 tgaccttggg tcctgaagtg acctcactgg cctgccatgc cagtaactgt gctgtactga 3120 gcactgaacc acattcaggg aaatggctta ttaaactttg aagcaactgt 3170 8 780 PRT Homo sapiens 8 Met Met Leu Leu Ala Thr Ser Gly Ala Cys Leu Gly Leu Leu Ala Val 1 5 10 15 Ala Ala Val Ala Ala Ala Gly Ala Asn Pro Ala Gln Arg Asp Thr His 20 25 30 Ser Leu Leu Pro Thr His Arg Arg Gln Lys Arg Asp Trp Ile Trp Asn 35 40 45 Gln Met His Ile Asp Glu Glu Lys Asn Thr Ser Leu Pro His His Val 50 55 60 Gly Lys Ile Lys Ser Ser Val Ser Arg Lys Asn Ala Lys Tyr Leu Leu 65 70 75 80 Lys Gly Glu Tyr Val Gly Lys Val Phe Arg Val Asp Ala Glu Thr Gly 85 90 95 Asp Val Phe Ala Ile Glu Arg Leu Asp Arg Glu Asn Ile Ser Glu Tyr 100 105 110 His Leu Thr Ala Val Ile Val Asp Lys Asp Thr Gly Glu Asn Leu Glu 115 120 125 Thr Pro Ser Ser Phe Thr Ile Lys Val His Asp Val Asn Asp Asn Trp 130 135 140 Pro Val Phe Thr His Arg Leu Phe Asn Ala Ser Val Pro Glu Ser Ser 145 150 155 160 Ala Val Gly Thr Ser Val Ile Ser Val Thr Ala Val Asp Ala Asp Asp 165 170 175 Pro Thr Val Gly Asp His Ala Ser Val Met Tyr Gln Ile Leu Lys Gly 180 185 190 Lys Glu Tyr Phe Ala Ile Asp Asn Ser Gly Arg Ile Ile Thr Ile Thr 195 200 205 Lys Ser Leu Asp Arg Glu Lys Gln Ala Arg Tyr Glu Ile Val Val Glu 210 215 220 Ala Arg Asp Ala Gln Gly Leu Arg Gly Asp Ser Gly Thr Ala Thr Val 225 230 235 240 Leu Val Thr Leu Gln Asp Ile Asn Asp Asn Phe Pro Phe Phe Thr Gln 245 250 255 Thr Lys Tyr Thr Phe Val Val Pro Glu Asp Thr Arg Val Gly Thr Ser 260 265 270 Val Gly Ser Leu Phe Val Glu Asp Pro Asp Glu Pro Gln Asn Arg Met 275 280 285 Thr Lys Tyr Ser Ile Leu Arg Gly Asp Tyr Gln Asp Ala Phe Thr Ile 290 295 300 Glu Thr Asn Pro Ala His Asn Glu Gly Ile Ile Lys Pro Met Lys Pro 305 310 315 320 Leu Asp Tyr Glu Tyr Ile Gln Gln Tyr Ser Phe Ile Val Glu Ala Thr 325 330 335 Asp Pro Thr Ile Asp Leu Arg Tyr Met Ser Pro Pro Ala Gly Asn Arg 340 345 350 Ala Gln Val Ile Ile Asn Ile Thr Asp Val Asp Glu Pro Pro Ile Phe 355 360 365 Gln Gln Pro Phe Tyr His Phe Gln Leu Lys Glu Asn Gln Lys Lys Pro 370 375 380 Leu Ile Gly Thr Val Leu Ala Met Asp Pro Asp Ala Ala Arg His Ser 385 390 395 400 Ile Gly Tyr Ser Ile Arg Arg Thr Ser Asp Lys Gly Gln Phe Phe Arg 405 410 415 Val Thr Lys Lys Gly Asp Ile Tyr Asn Glu Lys Glu Leu Asp Arg Glu 420 425 430 Val Tyr Pro Trp Tyr Asn Leu Thr Val Glu Ala Lys Glu Leu Asp Ser 435 440 445 Thr Gly Thr Pro Thr Gly Lys Glu Ser Ile Val Gln Val His Ile Glu 450 455 460 Val Leu Asp Glu Asn Asp Asn Ala Pro Glu Phe Ala Lys Pro Tyr Gln 465 470 475 480 Pro Lys Val Cys Glu Asn Ala Val His Gly Gln Leu Val Leu Gln Ile 485 490 495 Ser Ala Ile Asp Lys Asp Ile Thr Pro Arg Asn Val Lys Phe Lys Phe 500 505 510 Ile Leu Asn Thr Glu Asn Asn Phe Thr Leu Thr Asp Asn His Asp Asn 515 520 525 Thr Ala Asn Ile Thr Val Lys Tyr Gly Gln Phe Asp Arg Glu His Thr 530 535 540 Lys Val His Phe Leu Pro Val Val Ile Ser Asp Asn Gly Met Pro Ser 545 550 555 560 Arg Thr Gly Thr Ser Thr Leu Thr Val Ala Val Cys Lys Cys Asn Glu 565 570 575 Gln Gly Glu Phe Thr Phe Cys Glu Asp Met Ala Ala Gln Val Gly Val 580 585 590 Ser Ile Gln Ala Val Val Ala Ile Leu Leu Cys Ile Leu Thr Ile Thr 595 600 605 Val Ile Thr Leu Leu Ile Phe Leu Arg Arg Arg Leu Arg Lys Gln Ala 610 615 620 Arg Ala His Gly Lys Ser Val Pro Glu Ile His Glu Gln Leu Val Thr 625 630 635 640 Tyr Asp Glu Glu Gly Gly Gly Glu Met Asp Thr Thr Ser Tyr Asp Val 645 650 655 Ser Val Leu Asn Ser Val Arg Arg Gly Gly Ala Lys Pro Pro Arg Pro 660 665 670 Ala Leu Asp Ala Arg Pro Ser Leu Tyr Ala Gln Val Gln Lys Pro Pro 675 680 685 Arg His Ala Pro Gly Ala His Gly Gly Pro Gly Glu Met Ala Ala Met 690 695 700 Ile Glu Val Lys Lys Asp Glu Ala Asp His Asp Gly Asp Gly Pro Pro 705 710 715 720 Tyr Asp Thr Leu His Ile Tyr Gly Tyr Glu Gly Ser Glu Ser Ile Ala 725 730 735 Glu Ser Leu Ser Ser Leu Gly Thr Asp Ser Ser Asp Ser Asp Val Asp 740 745 750 Tyr Asp Phe Leu Asn Asp Trp Gly Pro Arg Phe Lys Met Leu Ala Glu 755 760 765 Leu Tyr Gly Ser Asp Pro Arg Glu Glu Leu Leu Tyr 770 775 780 

1. A method of treating glaucoma comprising, administering one or more cadherin inhibitors to a mammalian patient in need thereof, in an amount sufficient to inhibit a cadherin between Schlemm's canal cells to treat glaucoma in the mammalian patient.
 2. The method of claim 1, wherein the cadherin is VE-cadherin.
 3. The method of claim 1, wherein the mammalian patient is a human patient.
 4. The method of claim 1, wherein the administering comprises intravenous injection.
 5. The method of claim 1, wherein the administering comprises ocular administration.
 6. The method of claim 5, wherein the administration is topical.
 7. The method of claim 5, wherein the administration is ocular injection.
 8. The method of claim 1, wherein the one or more cadherin inhibitors is an antibody or antibody fragment.
 9. The method of claim 1, wherein the one or more cadherin inhibitors is a peptide.
 10. The method of claim 9, wherein the peptide comprises the amino acid sequence HAV.
 11. The method of claim 9, wherein the peptide comprises the amino acid sequence VIV.
 12. The method of claim 9, wherein the peptide comprises the amino acid sequence HAV and VIV.
 13. A method for screening for a substance that inhibits a cadherin between Schlemm's canal cells, comprising contacting the Schlemm's canal cells with the substance; and detecting the inhibition of the cadherin between the Schlemm's canal cells, which is indicative that the substance inhibits a cadherin between Schlemm's canal cells.
 14. The method of claim 13, wherein the Schlemm's canal cells are cultured cells.
 15. The method of claim 13, wherein the Schlemm's canal cells are cells obtained from a live tissue sample.
 16. The method of claim 13, wherein the Schlemm's canal cells are obtained from a post mortem eye.
 17. The method of claim 13, wherein the detecting comprises measuring an increase in hydraulic conductivity between the Schlemm's canal cells, wherein an increase in hydraulic conductivity is indicative that the substance inhibits a cadherin between Schlemm's canal cells.
 18. The method of claim 13, wherein the detecting comprises measuring transendothelial electrical resistance between the Schlemm's canal cells, wherein an increase in transendothelial electrical resistance is indicative that the substance inhibits a cadherin between Schlemm's canal cells.
 19. The method of claim 13, wherein the detecting comprises measuring transendothelial electrical resistance and hydraulic conductivity between the Schlemm's canal cells, wherein an increase in transendothelial electrical resistance and hydraulic conductivity is indicative that the substance inhibits a cadherin between Schlemm's canal cells.
 20. The method of claim 13, wherein the detecting comprises measuring outflow facility using a human anterior chamber perfusion model and increase in outflow facility is indicative that the substance inhibits cadherins between Schlemm's canal cells.
 21. The method of claim 13, wherein the detecting comprises measuring outflow facility using a live monkey and increase in outflow facility or decrease in intraocular pressure is indicative that the substance inhibits cadherins between Schlemm's canal cells.
 22. The method of claim 13, wherein the detecting comprises measuring the ability of the substance to affect adhesion of cultured Schlemm's canal cells to microtiter plates that have been precoated with a fusion protein comprising all or a portion of a extracellular domain of VE-cadherin. 